Avenue Therapeutics Inc. (NASDAQ: ATXI) stock jumped 6.00% on Monday to $1.59 against a previous-day closing price of $1.50. With 0.69 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.99 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.7000 whereas the lowest price it dropped to was $1.3500. The 52-week range on ATXI shows that it touched its highest point at $18.75 and its lowest point at $1.06 during that stretch. Beta for the stock currently stands at -0.59.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ATXI was up-trending over the past week, with a rise of 30.33%, but this was up by 20.45% over a month. Three-month performance dropped to -48.71% while six-month performance fell -63.65%. The stock lost -87.23% in the past year, while it has gained 37.07% so far this year.
Float and Shares Shorts:
At present, 4.78 million ATXI shares are outstanding with a float of 3.90 million shares on hand for trading. On Oct 13, 2022, short shares totaled 13550.0, which was 0.33% higher than short shares on Sep 14, 2022. In addition to Dr. Lindsay Allan Rosenwald as the firm’s Exec. Chairman, Dr. Xiaoqin Lu M.D. serves as its Consultant.
Through their ownership of 7.70% of ATXI’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 12.53% of ATXI, in contrast to 11.76% held by mutual funds. Shares owned by individuals account for 0.31%. As the largest shareholder in ATXI with 5.71% of the stake, Heights Capital Management, Inc. holds 272,700 shares worth 272,700. A second-largest stockholder of ATXI, Sabby Management LLC, holds 264,000 shares, controlling over 5.53% of the firm’s shares. Citadel Securities LLC is the third largest shareholder in ATXI, holding 35,865 shares or 0.75% stake. With a 0.18% stake in ATXI, the Vanguard Extended Market Index Fu is the largest stakeholder. A total of 8,335 shares are owned by the mutual fund manager. The Fidelity Extended Market Index Fu, which owns about 0.07% of ATXI stock, is the second-largest Mutual Fund holder. It holds 3,511 shares valued at 4073.0. Fidelity Nasdaq Composite Index F holds 0.03% of the stake in ATXI, owning 1,272 shares worth 1476.0.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ATXI since 1 analysts follow the stock currently. There are 0 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With ATXI analysts setting a high price target of $180.00 and a low target of $180.00, the average target price over the next 12 months is $180.00. Based on these targets, ATXI could surge 11220.75% to reach the target high and rise by 11220.75% to reach the target low. Reaching the average price target will result in a growth of 11220.75% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. ATXI will report FY 2021 earnings on 03/12/2024. Analysts have provided yearly estimates in a range of -$3.00 being high and -$3.00 being low. For ATXI, this leads to a yearly average estimate of -$3.00. Based on analyst estimates, the high estimate for the next quarter is -$0.60 and the low estimate is -$0.60. The average estimate for the next quarter is thus -$0.60.
Summary of Insider Activity:
Insiders traded ATXI stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has remained unchanged to 0 while that of sell transactions has risen to 1 over the past year. The total number of shares bought during that period was 0 while 388,888 shares were sold.